Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Company expects to provide Phase 1a interim data updates for CTIM-76 and CT-95 in 2026

Mar. 24, 2026 at 6:19am

Got story updates? Submit your updates here. ›

Context Therapeutics Inc., a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. The company expects to provide Phase 1a interim data for its CTIM-76 trial in June 2026 and its CT-95 trial in September 2026. Context also plans to dose the first patient in its CT-202 Phase 1 trial in the third quarter of 2026 and expects its current cash and cash equivalents to fund operations into mid-2027.

Why it matters

Context Therapeutics is developing a portfolio of T cell engaging bispecific antibodies for solid tumors, an area of high unmet medical need. The upcoming data readouts for CTIM-76 and CT-95 will provide important insights into the potential of these investigational therapies, while the initiation of the CT-202 trial represents an expansion of the company's pipeline. Maintaining a strong cash position will enable Context to continue advancing its programs.

The details

Context is evaluating CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody, in a Phase 1 dose escalation study for patients with ovarian, endometrial or testicular cancer. The company plans to complete the weekly dose escalation phase in the first half of 2026 and evaluate every three week dosing in the second half of the year. For CT-95, a Mesothelin x CD3 bispecific, Context is conducting a Phase 1a dose escalation study in patients with pancreatic, non-small cell lung, ovarian, mesothelioma and colorectal cancer. The company also completed regulatory filings to initiate a first-in-human trial for CT-202, a Nectin-4 x CD3 bispecific, and expects to dose the first patient in the third quarter of 2026.

  • Context expects to provide Phase 1a interim data for CTIM-76 in June 2026.
  • Context expects to provide Phase 1a interim data for CT-95 in September 2026.
  • Context expects to dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026.

The players

Context Therapeutics Inc.

A clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors.

Martin Lehr

CEO of Context Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors. We are on track to provide Phase 1a interim data for our CTIM-76 trial in June 2026. We are also continuing dose escalation for CT-95 toward target dose levels and expect to provide Phase 1a interim data for this trial in September 2026.”

— Martin Lehr, CEO

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Context Therapeutics is making progress in advancing its pipeline of T cell engaging bispecific antibodies for solid tumors, with key data readouts expected in 2026. The company's strong cash position will enable it to continue driving these programs forward as it works to develop innovative treatments for patients in need.